Moderna(MRNA.US)和默沙东(MRK.US)联合疗法对皮肤癌患者有积极疗效

智通财经2023-04-17

智通财经APP获悉，Moderna(MRNA.US)和默沙东(MRK.US)周日表示，一项关键的研究显示，与单独的免疫疗法相比，在重磅药物 Keytruda 中添加个性化癌症疫苗使更多的黑色素瘤患者得到缓解。两家公司在美国佛罗里达州奥兰多举行的美国癌症研究协会(AACR)年会上表示，在接受联合疗法的患者中，约79%的人在18个月后没有患癌症，而在仅接受默沙东Keytruda治疗的患者中，这一比例为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2328429445?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-04-17 08:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2328429445","market":"hk","top_or_hot":-1,"title":"Moderna(MRNA.US)和默沙东(MRK.US)联合疗法对皮肤癌患者有积极疗效","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，Moderna(MRNA.US)和默沙东(MRK.US)周日表示，一项关键的研究显示，与单独的免疫疗法相比，在重磅药物 Keytruda 中添加个性化癌症疫苗使更多的黑色素瘤患者得到缓解。两家公司在美国佛罗里达州奥兰多举行的美国癌症研究协会(AACR)年会上表示，在接受联合疗法的患者中，约79%的人在18个月后没有患癌症，而在仅接受默沙东Keytruda治疗的患者中，这一比例为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/911473.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna(MRNA.US)和默沙东(MRK.US)联合疗法对皮肤癌患者有积极疗效</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna(MRNA.US)和默沙东(MRK.US)联合疗法对皮肤癌患者有积极疗效\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-17 08:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/911473.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，Moderna(MRNA.US)和默沙东(MRK.US)周日表示，一项关键的研究显示，与单独的免疫疗法相比，在重磅药物 Keytruda 中添加个性化癌症疫苗使更多的黑色素瘤患者得到缓解。两家公司在美国佛罗里达州奥兰多举行的美国癌症研究协会(AACR)年会上表示，在接受联合疗法的患者中，约79%的人在18个月后没有患癌症，而在仅接受默沙东Keytruda治疗的患者中，这一比例为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/911473.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1023059063.AUD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/911473.html","article_id":"2328429445","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2328429445","pubTimestamp":1681692671,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，Moderna和默沙东周日表示，一项关键的研究显示，与单独的免疫疗法相比，在重磅药物 Keytruda 中添加个性化癌症疫苗使更多的黑色素瘤患者得到缓解。随着新冠疫苗需求降温，癌症疫苗是Moderna疫情后战略的重要组成部分。Moderna分析了每位患者肿瘤的基因序列，从而制造出一种疫苗，使免疫系统能够识别异常生长的标记物。默沙东和 Moderna 计划在已经使用 Keytruda 治疗的其他癌症中测试该联合疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4516":"特朗普概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4532":"文艺复兴科技持仓","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4007":"制药","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4559":"巴菲特持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","BK4501":"段永平概念","LU0861579265.USD":"联博低波幅策略股票基金A","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","MRNA":"Moderna, Inc.","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","BK4551":"寇图资本持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014542.SGD":"United Income Focus Trust Acc SGD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4548":"巴美列捷福持仓","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc"},"translate_title":"Combination therapy of Moderna (MRNA. US) and Mercadon (MRK. US) has a positive effect on skin cancer patients","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"智通财经APP获悉，Moderna(MRNA.US)和默沙东(MRK.US)周日表示，一项关键的研究显示，与单独的免疫疗法相比，在重磅药物 Keytruda 中添加个性化癌症疫苗使更多的黑色素瘤患者得到缓解。两家公司在美国佛罗里达州奥兰多举行的美国癌症研究协会(AACR)年会上表示，在接受联合疗法的患者中，约79%的人在18个月后没有患癌症，而在仅接受默沙东Keytruda治疗的患者中，这一比例为62%。他们表示，该疫苗的副作用通常很轻微，比如疲劳。随着新冠疫苗需求降温，癌症疫苗是Moderna疫情后战略的重要组成部分。默沙东首席医疗官Eliav Barr表示，研究结果表明这种联合疗法是有效的，在寻求美国批准之前，两家公司可能需要在更大规模的后期试验中证明这种疗效。虽然Moderna高管早些时候曾表示，两家公司可能会根据中期结果寻求加速批准，但Barr表示，他们正准备首先完成今年晚些时候开始的第三阶段研究。休斯顿MD Anderson癌症中心的黑色素瘤医学肿瘤学家Sapna Patel表示，在会议上展示的详细数据表明，应该在更多的患者中研究这种治疗方法。Patel表示:“它看起来比标准疗法更有效，需要进行第三阶段研究才能证明它真正有效。”在此次试验中，患者在手术切除黑色素瘤后接受了这两种药物。Moderna分析了每位患者肿瘤的基因序列，从而制造出一种疫苗，使免疫系统能够识别异常生长的标记物。患者每三周注射一次，总共注射九次。他们还每三周接受一次Keytruda治疗，最多进行 18 次治疗。默沙东和 Moderna 计划在已经使用 Keytruda 治疗的其他癌症中测试该联合疗法。Barr表示，他们的目标是在开始下一次黑色素瘤试验后不久开展一项肺癌研究。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2328429445"}